

EXHIBIT E

Applicants: James M. Binley et al.

Serial No.: 10/780,993

Filed: February 18, 2004



Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
59331-E
JPW/MAF/AJDSerial No.
10/780,993INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicant(s)
James M. Binley et al.Filing Date
February 18, 2004

Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initials	Pub. No.	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
		5 8 8 6 1 6 3	03/23/99	Binley et al.			
		5 9 3 5 5 7 9	08/10/99	Habeshaw et al.			
	1	Allowed claims in U.S. Serial No. 09/602,864		Binley et al.			06/23/00

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Atwell, S. et al. (1997) Stable Heterodimers from Remodeling the Domain Interface of a Homodimer using a Phage Display Library, <i>J. Mol. Biol.</i> 270: 26-35;
	Barouch, D.H. and N.L. Letvin (2000) DNA Vaccination for HIV-1 and SIV, <i>Intervirology</i> 4: 282-287;
	Barouch, D.H. et al. (2002) Eventual AIDS Vaccine Failure in a Rhesus Monkey by Viral Escape from Cytotoxic T Lymphocytes, <i>Nature</i> 415: 335-339;
	Binley, J. et al. (2000) A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond Between the GP 120 and GP 41 Subunits is an Antigenic Mimic of the Trimeric Viron-Associated Structure, <i>J. Virol.</i> 74: 627-643;
	Burton, D.R. et al. (1994) Efficient Neutralization of Primary Isolates of HIV-1 by a Recombinant Human Monoclonal Antibody. <i>Science</i> 266: 1024-1027;
	Burton, D.R. and J.P. Moore (1998) Why do we Not Have an HIV Vaccine and how Can we Make One? <i>Nature Med.</i> Vaccine Suppl. 4(5): 495-498;
	Cao, J. et al. (1997) Replication and Neutralization of Human Immunodeficiency Virus Type 1 Lacking the V1 and V2 Variable Loops of the gp120 Envelope Glycoprotein, <i>J. Virol.</i> 71: 9808-9812;

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
59331-E
/JPW/MAF/AJDSerial No.
10/780,993INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicant(s)
James M. Binley et al.Filing Date
February 18, 2004

Group Art Unit

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

- Edinger, A.L. et al. (1999) Functional Dissection of CCR5 Coreceptor Function through the Use of CD4-Independent Simian Immunodeficiency Virus Strains, *J. Virol.* 73: 4062-4073;
- Farzan, M. et al. (1998) Stabilization of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers by Disulfide Bonds Introduced into the GP 41 Glycoprotein Ectodomain, *J. Virol.* 72: 7620-7625;
- Fouts, T.R. et al. (1998) Interactions of Polyclonal and Monoclonal Anti-Glycoprotein 120 Antibodies with Oligomeric Glycoprotein 120-Glycoprotein 41 Complexes of a Primary HIV Type 1 Isolate: Relationship to Neutralization, *AIDS Res. Human Retrovir.* 14: 591-597;
- Fouts, T.R. et al. (1997) Neutralization of the Human Immunodeficiency Virus Type 1 Primary Isolate JR-FL by Human Monoclonal Antibodies Correlates with Antibody Binding to the Oligomeric Form of the Envelope glycoprotein Complex, *J. Virol.* 71: 2779-2785;
- Gillagher, W.R. et al. (1995) A General Model for the Surface Glycoproteins of HIV and Other Retroviruses, *AIDS Res. Human Retrovir.* 11: 191-202;
- Haynes, B.F. (1996) HIV Vaccines: Where are we and Where are we Going? *Lancet* 348: 933-937;
- Helseth, E. et al. (1991) Human Immunodeficiency Virus Type 1 gp120 envelope Glycoprotein Regions Important for Association with the gp41 Transmembrane Glycoprotein, *J. Virol.* 65(4): 2119-2123;
- Johnston, M.I. and J. Flores (2001) Progress in HIV Vaccine Development, *Curr. Opin. Pharmacol.* 1(5): 504-510;
- Joy, A.K. et al. (1999) Can HIV Infection be Prevented with a Vaccine? *Drugs R&D* 6: 431-440;
- Labranche, C.C. et al. (1994) Biological, Molecular, and Structural Analysis of a Cytopathic Variant from a Molecularly Cloned Simian Immunodeficiency Virus. *J. Virol.* 68: 5509-5522;
- Labranche, C.C. et al. (1994) Biological, Molecular, and Structural Analysis of a Cytopathic Variant from a Molecularly Cloned Simian Immunodeficiency Virus. *J. Virol.* 68: 7665-7667;
- Maerz, A.L. et al. (2001) Functional Analysis of the Disulfide-Bonded Loop/Chain Reversal Region of Human Immunodeficiency Virus Type 1 gp41 reveals a Critical Role in gp120-gp41 Association, *J. Virol.* 75(14): 6635-6644;
- McInerney, T.L. et al. (1998) Mutation-Directed Chemical Cross-Linking of Human Immunodeficiency Virus Type 1 gp41 Oligomers, *J. Virol.* 72: 1523-1533;
- Mitchell, W.M. et al. (1998) Inactivation of a Common Epitope Responsible for the Induction of Antibody-Dependent Enhancement of HIV, *AIDS* 12: 147-156;

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeINFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Atty. Docket No.

59331-E

Serial No.

10/780,993

JPW/MAF/AJD

Applicant(s)

James M. Binley et al.

Filing Date

February 18, 2004

Group Art Unit

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Moore, J.P. et al. (1994a) "Probing the Structure of the Human Immunodeficiency Virus Surface Glycoprotein gp120 with a Panel of Monoclonal Antibodies, J. Virol. 68: 469-484;

Moore, J.P. et al. (1994b) Immunological Evidence for Interactions between the First, Second, and Fifth Conserved Domains to the gp120 Surface Glycoprotein of Human Immunodeficiency Virus Type 1, J. Virol. 68(11): 6836-6847;

Murphy, F.A. (1996) "Virus Taxonomy," in Fields Virology, Third Edition, B.N. Fields, et al. eds., Lippincott-Raven Publisher, Philadelphia, pp. 40 and 41;

Parren, P.W. et al. (1997) HIV-1 Antibody - Debris or Virion? Nat. Med. 3: 366-367;

Parren, P.W. et al. (1998) Neutralization of Human Immunodeficiency Virus Type 1 by Antibody to gp120 is Determined Primarily by Occupancy of Sites on the Virion Respective of Epitope Specificity," J. Virol. 72: 3512-3519;

Reitter, J.N. et al. (1998) A Role for Carbohydrates in Immune Evasion in AIDS, Nat. Med. 4: 679-684;

Schulz, T.F. et al. (1992) Conserved Structural Features in the Interaction between Retroviral Surface and Transmembrane Glycoproteins? AIDS Res. Hum. Retrovirus 8(9): 1571-1580;

Stamatatos, L. et al. (1994) Differential Regulation of Cellular Tropism and Sensitivity to Soluble CD4 Neutralization by the Envelope gp120 of Human Immunodeficiency Virus Type 1, J. Virol. 68: 4973-4979; and

Trkola, A. et al. (1996) Human Monoclonal Antibody 2G12 Defines a Distinctive Neutralization Epitope on the gp120 Glycoprotein of Human Immunodeficiency Virus Type 1. J. Virol. 70: 1100-1108.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
59331-E
JPW/AJD/BWSLSerial No.
10780,993INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicant(s)
James M. Binley et al.Filing Date
February 18, 2004

Art Unit

U.S. PATENT DOCUMENTS

Examiner Initials	Pub No	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
1	5	4 7 4 9 1 4	12/12/95	Spacte			
2	6	1 7 1 5 9 6	01/09/01	Earl et al.			
	60	1 4 1 1 6 8		Binley et al.			06/25/99
3	09	3 4 0 9 9 2		Binley et al.			06/25/99
4	2	0 0 3 7 0 0 5 2 8 3 9	03/20/03	Binley et al.			
5	10	1 1 7 3 6 6		Binley et al.			04/05/02
	60	3 7 0 4 1 0		Binley et al.			04/05/02
6	60	3 1 7 9 0 9		Binley et al.			09/06/01
7		Claims Filed in 60/317,764		Binley et al.			09/06/01
8	60	3 1 7 9 1 0		Moore et al.			09/06/01
9		Claims Filed in 60/317,775		Moore et al.			09/06/01
10	60	3 7 0 2 6 4					04/05/02
11		Pending Claims in 10/489,040		Moore et al.			03/05/04
12	60	5 8 0 2 2 9		Schuelke et al.			06/15/04

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
13	0 1 0 0 6 4 8	01/04/01	PCT				
14	03 0 2 2 8 6 9	03/20/03	PCT				
15	03 0 8 7 7 5 7	10/23/03	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

16	Cao, J., et al. (1993) Effects of Amino Acid Changes in the Extracellular Domain of the Human Immunodeficiency Virus Type 1 gp41 Envelope Glycoprotein, <u>J. Virol.</u> 67(5):2747-2755; and
17	Letvin, N.L., 1998, Progress in the Development of an HIV-1 Vaccine, <u>Science</u> 280:1875-1880.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce	Application Number	10/780,993
Patent and Trademark Office		Filing Date	February 18, 2004
		First Named Inventor	James M. Binley et al.
INFORMATION DISCLOSURE STATEMENT		Art Unit	
(Use several sheets if necessary)		Examiner Name	
		Attorney Docket No.	59331-AA

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials	Chie No.	Foreign Patent Document 'Country Code' 'Number' 'Kind Code'	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁴
		WO 2006/002079	01-05-2006		

**EXAMINER
SIGNATURE**

DATE CONSIDERED

*EXAMINER'S: Initial of citation considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Include copy of this form with nearest communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 201.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST 16). *For Japanese patent documents, the indication of the year of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. *Applicant is to place a check mark here if English Language Translation is attached.

Applicants: James M. Binley et al.

Pat. No.: 10,730,993

Filed: February 18, 2004

• **habit 9**

Patent and Trademark Office

Application Number	10/780,993
Filing Date	February 18, 2004
First Named Inventor	James M. Binley et al.
Art Unit	
Examiner Name	
Attorney Docket No.	59331-AA

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
		Binley, J.M. et al. (2002) "Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins." J. of Virology, Vol 76 No. 6 pages 2606-2616	
		Chen, S. (1993) "Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein" J. of Virology, June 1993, Vol. 67, No. 6, p. 3615-3619	
		Crisson J. (1999) "The Mode and Duration of Anti-CD28 Costimulation Determine Resistance to Infection by Macrophage-Tropic Strains of Human Immunodeficiency Virus Type 1 in Vitro" Journal of Virology, Nov. 1999, Vol. 73, No. 11, p. 9337-9347	
		Ditzel H J et al. (1997) "Mapping the protein surface of human immunodeficiency virus type 1 gp 120 using human monoclonal antibodies from phage display libraries" J. of Molecular Biology, Vol. 267 No. 3, pages 684-695	
		Haynes, B.F. (1996) "Update on the Issues of HIV Vaccine Development" Ann. Med. 28:39-41	
		Nakashe, J. et al., (2001) "Rectal immunization with antigen-containing microspheres induces stronger Th2 responses than oral immunization: a new method for vaccination" Vaccine, Butterworth Scientific Guildford, GB, Vol. 20, no. 3-4, pages 377-384	
		Parker, Carole, et al. (2001) "Fine Definition of the Epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5" J. of Virol. Vol. 75, No. 22, pages 10906-10911	
		Sanders R. et al., (2002) "Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1." Journal of Virology, Vol. 76, No. 17, p.8875-8889	
		Sanders R. (2000) "Variable-Loop-Deleted Variants of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Can Be Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits" Journal of Virology, June 2000, Vol. 74, No. 11, p.5091-5100	
		Schulke, Norber et al. (2002) "Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein." J. of Virology, Vol 76 No. 15, pages 7760-7776	

EXAMINER
SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *Applicant is to place a checkmark here if English language translation is attached.

